Radius Health Stock Price, News & Analysis (NASDAQ:RDUS)

$37.91 -0.66 (-1.71 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$37.91
Today's Range$37.50 - $39.13
52-Week Range$24.66 - $49.16
Volume384,256 shs
Average Volume892,495 shs
Market Capitalization$1.66 billion
P/E Ratio-6.98
Dividend YieldN/A
Beta1.21

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RDUS
CUSIPN/A
Phone+1-617-5514000

Debt

Debt-to-Equity Ratio0.53%
Current Ratio12.87%
Quick Ratio12.79%

Price-To-Earnings

Trailing P/E Ratio-6.98158379373849
Forward P/E Ratio-6.73
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.12 per share
Price / Book5.32

Profitability

Trailing EPS($5.43)
Net Income$-182,800,000.00
Net MarginsN/A
Return on Equity-87.19%
Return on Assets-68.29%

Miscellaneous

Employees237
Outstanding Shares44,590,000

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) released its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by $0.03. The biopharmaceutical company had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same period in the prior year, the firm earned ($1.07) earnings per share. View Radius Health's Earnings History.

Where is Radius Health's stock going? Where will Radius Health's stock price be in 2018?

10 brokers have issued 1 year target prices for Radius Health's shares. Their predictions range from $24.00 to $85.00. On average, they expect Radius Health's share price to reach $51.78 in the next twelve months. View Analyst Ratings for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:

  • 1. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months." (1/8/2018)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
  • 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)

Are investors shorting Radius Health?

Radius Health saw a increase in short interest in the month of January. As of January 12th, there was short interest totalling 11,252,920 shares, an increase of 18.5% from the December 29th total of 9,494,332 shares. Based on an average daily trading volume, of 975,391 shares, the short-interest ratio is presently 11.5 days. Currently, 27.7% of the company's shares are short sold.

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:

  • Kurt C. Graves, Independent Chairman of the Board (Age 49)
  • Jesper Hoiland, President, Chief Executive Officer, Director (Age 56)
  • Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer (Age 45)
  • Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer (Age 50)
  • Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary (Age 52)
  • Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 63)
  • Gregory Williams Ph.D., Chief Development Officer (Age 58)
  • Willard H. Dere M.D., Independent Director (Age 63)
  • Catherine J. Friedman, Independent Director (Age 56)
  • Jean-Pierre Garnier Ph.D., Independent Director (Age 69)

Who owns Radius Health stock?

Radius Health's stock is owned by many different of retail and institutional investors. Top institutional investors include Consonance Capital Management LP (5.94%), TimesSquare Capital Management LLC (4.20%), Franklin Resources Inc. (0.90%), Hudson Bay Capital Management LP (0.45%), Candriam Luxembourg S.C.A. (0.44%) and Eversept Partners LLC (0.44%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Institutional Ownership Trends for Radius Health.

Who sold Radius Health stock? Who is selling Radius Health stock?

Radius Health's stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Alliancebernstein L.P., ING Groep NV, Highland Capital Management LP, Franklin Resources Inc., Guggenheim Capital LLC, Metropolitan Life Insurance Co. NY and Rhumbline Advisers. View Insider Buying and Selling for Radius Health.

Who bought Radius Health stock? Who is buying Radius Health stock?

Radius Health's stock was acquired by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, TimesSquare Capital Management LLC, Eversept Partners LLC, Prosight Management LP, Crestline Management LP, Candriam Luxembourg S.C.A., Hudson Bay Capital Management LP and Alps Advisors Inc.. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.

How do I buy Radius Health stock?

Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of Radius Health stock can currently be purchased for approximately $37.91.

How big of a company is Radius Health?

Radius Health has a market capitalization of $1.66 billion. The biopharmaceutical company earns $-182,800,000.00 in net income (profit) each year or ($5.43) on an earnings per share basis. Radius Health employs 237 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 Winter St, WALTHAM, MA 02451-1424, United States. The biopharmaceutical company can be reached via phone at +1-617-5514000 or via email at [email protected]


MarketBeat Community Rating for Radius Health (RDUS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  500
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Radius Health (NASDAQ:RDUS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.602.562.632.43
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.78$48.00$51.00$53.60
Price Target Upside: 47.26% upside41.76% upside76.10% upside45.51% upside

Radius Health (NASDAQ:RDUS) Consensus Price Target History

Price Target History for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018JPMorgan Chase & Co.Lower Price TargetOverweight$70.00 -> $60.00MediumView Rating Details
1/29/2018Morgan StanleyInitiated CoverageOverweight -> Overweight$57.00MediumView Rating Details
1/22/2018CitigroupReiterated RatingHold$43.00MediumView Rating Details
1/18/2018Cantor FitzgeraldReiterated RatingBuy$58.00HighView Rating Details
11/3/2017Jefferies GroupLower Price TargetHold$38.00 -> $31.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$45.00N/AView Rating Details
9/29/2017Maxim GroupReiterated RatingPositiveMediumView Rating Details
7/31/2017Canaccord GenuitySet Price TargetBuy$85.00MediumView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017CowenDowngradeOutperform -> Market PerformLowView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Radius Health (NASDAQ:RDUS) Earnings History and Estimates Chart

Earnings by Quarter for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ RDUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($1.28)($1.31)$6.90 million$13.50 millionViewN/AView Earnings Details
8/3/2017Q2 2017($1.35)($1.58)$1.96 million$0.98 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.18)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Radius Health (NASDAQ:RDUS) Earnings Estimates

Current Year EPS Consensus Estimate: $-5.63 EPS
Next Year EPS Consensus Estimate: $-4.99 EPS

Dividends

Dividend History for Radius Health (NASDAQ:RDUS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.00%
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ RDUS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Growth N V BiotechMajor ShareholderBuy75,000$34.38$2,578,500.005,773,799View SEC Filing  
11/14/2017Growth N V BiotechMajor ShareholderBuy50,000$26.25$1,312,500.005,698,799View SEC Filing  
11/10/2017Brent Hatzis-SchochVPBuy1,778$28.09$49,944.022,278View SEC Filing  
11/7/2017Jesper HoilandInsiderBuy6,800$29.04$197,472.0012,900View SEC Filing  
11/3/2017Growth N V BiotechMajor ShareholderBuy50,000$29.15$1,457,500.005,648,799View SEC Filing  
10/25/2017Growth N V BiotechMajor ShareholderBuy50,000$32.85$1,642,500.005,548,799View SEC Filing  
9/15/2017Jesper HoilandInsiderBuy6,100$32.72$199,592.006,100View SEC Filing  
9/14/2017Growth N V BiotechMajor ShareholderBuy150,000$33.45$5,017,500.005,448,799View SEC Filing  
9/14/2017Jose CarmonaCFOBuy3,000$32.83$98,490.003,000View SEC Filing  
9/12/2017Growth N V BiotechMajor ShareholderBuy50,000$35.42$1,771,000.005,348,799View SEC Filing  
9/5/2017Growth N V BiotechMajor ShareholderBuy50,000$36.75$1,837,500.005,298,799View SEC Filing  
8/16/2017Growth N V BiotechMajor ShareholderBuy60,000$35.98$2,158,800.005,248,799View SEC Filing  
8/10/2017Growth N V BiotechMajor ShareholderBuy150,000$34.97$5,245,500.005,113,799View SEC Filing  
5/30/2017Growth N V BiotechMajor ShareholderBuy40,000$34.21$1,368,400.005,038,799View SEC Filing  
5/25/2017Growth N V BiotechMajor ShareholderBuy40,000$36.25$1,450,000.004,998,799View SEC Filing  
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.004,958,799View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.004,890,799View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.004,873,799View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.004,858,799View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.004,785,999View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.004,765,399View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.004,690,399View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.004,540,399View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.004,490,399View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.374,415,930View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.434,398,678View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.534,360,399View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.004,322,140View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.004,272,140View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Radius Health (NASDAQ RDUS) News Headlines

Source:
DateHeadline
Form 4 Radius Health, Inc. For: Feb 13 Filed by: Hughes OwenForm 4 Radius Health, Inc. For: Feb 13 Filed by: Hughes Owen
www.streetinsider.com - February 16 at 8:36 AM
Radius Health (RDUS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowRadius Health (RDUS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 5:05 PM
Radius Health to Present at 2018 RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)Radius Health to Present at 2018 RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 15 at 8:08 AM
Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018
finance.yahoo.com - February 14 at 9:39 AM
Radius Health to Present at 2018 RBC Capital Markets Global Healthcare ConferenceRadius Health to Present at 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 14 at 9:39 AM
Radius Health Inc (RDUS) Given Average Recommendation of "Hold" by BrokeragesRadius Health Inc (RDUS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 9:38 AM
Growth N. V. Biotech Acquires 75,000 Shares of Radius Health Inc (RDUS) StockGrowth N. V. Biotech Acquires 75,000 Shares of Radius Health Inc (RDUS) Stock
www.americanbankingnews.com - February 12 at 6:32 PM
Radius Health (RDUS) Given New $60.00 Price Target at JPMorgan Chase & Co.Radius Health (RDUS) Given New $60.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - February 12 at 11:46 AM
Radius Health to Present at Leerink Partners 7th Annual Global Healthcare ConferenceRadius Health to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:26 AM
Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer PipelineAnalyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline
finance.yahoo.com - January 29 at 3:57 PM
Radius Health (RDUS) Coverage Initiated by Analysts at Morgan StanleyRadius Health (RDUS) Coverage Initiated by Analysts at Morgan Stanley
www.americanbankingnews.com - January 29 at 12:42 PM
Radius Health Inc (RDUS) Sees Significant Growth in Short InterestRadius Health Inc (RDUS) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 27 at 2:10 AM
Stock Traders Purchase High Volume of Call Options on Radius Health (RDUS)Stock Traders Purchase High Volume of Call Options on Radius Health (RDUS)
www.americanbankingnews.com - January 22 at 2:32 AM
Cantor Fitzgerald Comments on Radius Health Incs FY2017 Earnings (RDUS)Cantor Fitzgerald Comments on Radius Health Inc's FY2017 Earnings (RDUS)
www.americanbankingnews.com - January 22 at 1:48 AM
-$1.49 EPS Expected for Radius Health Inc (RDUS) This Quarter-$1.49 EPS Expected for Radius Health Inc (RDUS) This Quarter
www.americanbankingnews.com - January 20 at 7:16 AM
Radius Health Inc (RDUS) Given Average Rating of "Hold" by BrokeragesRadius Health Inc (RDUS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 19 at 8:18 AM
Radius Health (RDUS) Given "Buy" Rating at Cantor FitzgeraldRadius Health (RDUS) Given "Buy" Rating at Cantor Fitzgerald
www.americanbankingnews.com - January 18 at 8:28 AM
Biotech Stocks Near Massive BreakoutBiotech Stocks Near Massive Breakout
finance.yahoo.com - January 12 at 3:33 PM
Radius Health (RDUS) Upgraded at Zacks Investment ResearchRadius Health (RDUS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 8 at 12:38 PM
Head-To-Head Review: Radius Health (RDUS) versus Zymeworks (ZYME)Head-To-Head Review: Radius Health (RDUS) versus Zymeworks (ZYME)
www.americanbankingnews.com - January 7 at 11:26 PM
Radius Health to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Radius Health to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 6 at 3:36 PM
$6.87 Million in Sales Expected for Radius Health Inc (RDUS) This Quarter$6.87 Million in Sales Expected for Radius Health Inc (RDUS) This Quarter
www.americanbankingnews.com - January 5 at 11:52 AM
Radius Health to Present at the 36th Annual J.P. Morgan Healthcare ConferenceRadius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 11:12 AM
Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications - GlobeNewswire (press release)Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications - GlobeNewswire (press release)
globenewswire.com - January 2 at 8:52 PM
Radius Health (RDUS) Rating Lowered to Sell at Zacks Investment ResearchRadius Health (RDUS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Radius Health Welcomes Elhan Webb as Head of Investor Relations and External CommunicationsRadius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications
finance.yahoo.com - January 2 at 11:10 AM
Radius Health (RDUS) Raised to Sell at BidaskClubRadius Health (RDUS) Raised to Sell at BidaskClub
www.americanbankingnews.com - December 27 at 9:53 AM
Radius Health Inc (RDUS) Receives Consensus Recommendation of "Hold" from BrokeragesRadius Health Inc (RDUS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 25 at 8:06 AM
Radius Health to Get Third Day-180 List of Outstanding Issues - NasdaqRadius Health to Get Third Day-180 List of Outstanding Issues - Nasdaq
www.nasdaq.com - December 19 at 3:35 PM
Wired News – Radius Health Expects CHMP to Issue Third Day-180 List of Outstanding Issues in Its Regulatory Review of Abaloparatide-SCWired News – Radius Health Expects CHMP to Issue Third Day-180 List of Outstanding Issues in Its Regulatory Review of Abaloparatide-SC
finance.yahoo.com - December 18 at 11:40 AM
Radius Health (RDUS) Announces CHMP Will Issue Third Day-180 List of ...Radius Health (RDUS) Announces CHMP Will Issue Third Day-180 List of ...
www.streetinsider.com - December 16 at 3:34 PM
Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue aRadius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a
www.nasdaq.com - December 15 at 3:39 PM
Radius Health (RDUS) Given a $58.00 Price Target by Cantor Fitzgerald AnalystsRadius Health (RDUS) Given a $58.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 15 at 12:50 PM
Radius Health not quite there with European marketing application for osteoporosis med abaloparatide; shares down 3 ... - Seeking AlphaRadius Health not quite there with European marketing application for osteoporosis med abaloparatide; shares down 3 ... - Seeking Alpha
seekingalpha.com - December 15 at 11:47 AM
Radius Health (RDUS) Announces CHMP Will Issue Third Day-180 ... - StreetInsider.comRadius Health (RDUS) Announces CHMP Will Issue Third Day-180 ... - StreetInsider.com
www.streetinsider.com - December 15 at 11:47 AM
Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Building Agent for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of FractureRadius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Building Agent for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture
finance.yahoo.com - December 15 at 11:47 AM
Radius Health, Inc. – Value Analysis (NASDAQ:RDUS) : December 13, 2017Radius Health, Inc. – Value Analysis (NASDAQ:RDUS) : December 13, 2017
finance.yahoo.com - December 13 at 3:36 PM
Radius Health, Inc. breached its 50 day moving average in a Bearish Manner : RDUS-US : December 12, 2017Radius Health, Inc. breached its 50 day moving average in a Bearish Manner : RDUS-US : December 12, 2017
finance.yahoo.com - December 12 at 11:56 AM
Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical IndustryFractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry
finance.yahoo.com - December 11 at 3:33 PM
BidaskClub Downgrades Radius Health (RDUS) to Strong SellBidaskClub Downgrades Radius Health (RDUS) to Strong Sell
www.americanbankingnews.com - December 9 at 1:38 PM
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in ...Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in ...
globenewswire.com - December 8 at 3:35 PM
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer SymposiumRadius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 8 at 3:35 PM
Here's Why Radius Health Is Rising TodayHere's Why Radius Health Is Rising Today
finance.yahoo.com - December 8 at 3:35 PM
Radius Health Breast Cancer Trial Continues to Show Progress - 24/7 Wall St.Radius Health Breast Cancer Trial Continues to Show Progress - 24/7 Wall St.
247wallst.com - December 8 at 11:42 AM
Radius Health Breast Cancer Trial Continues to Show ProgressRadius Health Breast Cancer Trial Continues to Show Progress
finance.yahoo.com - December 8 at 11:42 AM
Citigroup Begins Coverage on Radius Health (RDUS)Citigroup Begins Coverage on Radius Health (RDUS)
www.americanbankingnews.com - December 6 at 7:51 PM
Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium ... - GlobeNewswire (press release)Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium ... - GlobeNewswire (press release)
globenewswire.com - December 5 at 3:35 PM
Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)
finance.yahoo.com - December 4 at 11:46 AM
Radius Health (RDUS) Rating Increased to Sell at ValuEngineRadius Health (RDUS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 7:44 PM
$6.87 Million in Sales Expected for Radius Health, Inc. (RDUS) This Quarter$6.87 Million in Sales Expected for Radius Health, Inc. (RDUS) This Quarter
www.americanbankingnews.com - December 1 at 3:08 AM

SEC Filings

Radius Health (NASDAQ:RDUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Radius Health (NASDAQ RDUS) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.